Two Sigma Advisers
DSGN icon

Two Sigma Advisers’s Design Therapeutics DSGN Stock Holding History

Two Sigma Advisers’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,300
Closed -$237K – 626
2025
Q4 		$237K Sell
25,300
-15,200
-38% -$119K ﹤0.01% 2055
2025
Q3 		$305K Sell
40,500
-68,000
-63% -$341K ﹤0.01% 1982
2025
Q2 		$366K Sell
108,500
-38,200
-26% -$143K ﹤0.01% 1884
2025
Q1 		$566K Sell
146,700
-87,200
-37% -$416K ﹤0.01% 1723
2024
Q4 		$1.44M Sell
233,900
-71,000
-23% -$411K ﹤0.01% 1282
2024
Q3 		$1.64M Sell
304,900
-95,200
-24% -$448K ﹤0.01% 1176
2024
Q2 		$1.34M Sell
400,100
-3,900
-1% -$15.2K ﹤0.01% 1401
2024
Q1 		$1.63M Sell
404,000
-181,000
-31% -$483K ﹤0.01% 1329
2023
Q4 		$1.55M Buy
585,000
+472,200
+419% +$1.08M ﹤0.01% 1423
2023
Q3 		$266K Buy
112,800
+33,800
+43% +$158K ﹤0.01% 2016
2023
Q2 		$498K Buy
79,000
+32,300
+69% +$198K ﹤0.01% 1809
2023
Q1 		$269K Buy
+46,700
New +$349K ﹤0.01% 2178

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Advisers's DSGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 25,300 shares — an estimated $237K sold.

Two Sigma Advisers first reported a position in DSGN in Q1 2023 and held it in 12 quarters. The position peaked at $1.64M in Q3 2024. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Two Sigma Advisers reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 25,300 Design Therapeutics shares in Q1 2026, an estimated $237K.
  • Two Sigma Advisers first reported a position in Design Therapeutics in Q1 2023 and held it in 12 quarters.
  • Two Sigma Advisers's Design Therapeutics position peaked at $1.64M in Q3 2024.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.